Krystal Biotech's (KRYS) beremagene geperpavec to treat wounds in patients with dystrophic epidermolysis bullosa has received approval from the UK's Medicines and Healthcare products Regulatory Agency for use from birth onward, the agency said in a Friday statement.
The medication, which is available in the form of gel, demonstrated 67% complete healing rate in a study of 31 patients at six months, according to the statement.
Dystrophic epidermolysis bullosa is a rare genetic condition characterized by fragile skin and recurrent wounds.
Price: 308.93, Change: -7.37, Percent Change: -2.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments